StockNews.AI
TVTX
StockNews.AI
78 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX

1. Pomerantz LLP is investigating Travere for possible securities fraud. 2. FDA plans to discuss Travere's sNDA for FILSPARI's approval. 3. Following the news, Travere's stock fell 20.57% to $16.80. 4. Investors are encouraged to contact Pomerantz for class action participation.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The investigation into potential securities fraud raises severe credibility risks for TVTX. Such allegations can lead to a significant loss of investor confidence, often resulting in stock price declines, similar to past incidents with other biotech firms facing fraud claims.

How important is it?

The ongoing investigation and significant stock drop indicate a direct relationship to TVTX’s market perception. The involvement of a reputable law firm adds weight to the seriousness of the allegations.

Why Short Term?

The immediate fallout from the investigation and stock price decline is likely to impact TVTX soon. Historical precedents show that investigations typically create quick volatility in stock prices.

Related Companies

NASDAQ: FDA
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Travere and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 15, 2025, Travere issued a press release disclosing that the U.S. Food and Drug Administration (“FDA”) “has indicated that it is currently planning to hold an advisory committee meeting to discuss” the Company’s “supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS).”  On this news, Travere’s stock price fell $4.35 per share, or 20.57%, to close at $16.80 per share on May 16, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News